国际呼吸杂志
國際呼吸雜誌
국제호흡잡지
INTERNATIONAL JOURNAL OF RESPIRATION
2012年
18期
1396-1398
,共3页
陈明勇%陈勃江%陈斌%刘小英
陳明勇%陳勃江%陳斌%劉小英
진명용%진발강%진빈%류소영
稳定期慢性阻塞性肺疾病%肺表面活性物质相关蛋白D%沙美特罗%沙美特罗替卡松
穩定期慢性阻塞性肺疾病%肺錶麵活性物質相關蛋白D%沙美特囉%沙美特囉替卡鬆
은정기만성조새성폐질병%폐표면활성물질상관단백D%사미특라%사미특라체잡송
Stable chronic obstructive pulmonary disease%Surfactant protein-D%Salmeterol%Salmeterol/fluticasone
目的 探讨吸入沙美特罗替卡松粉剂对慢性阻塞性肺疾病(chronic obstructive pulmonary disease,COPD)稳定期患者血清肺表面活性物质相关蛋白D(surfactant associated protein D,SP-D)浓度的影响.方法 选择Ⅲ级及Ⅳ级稳定期COPD患者84例,随机分为沙美特罗(50μg)和沙美特罗替卡松粉剂(50 μg/500 μg)两组,每组42例,每例患者均吸入2次/日,每次1吸,疗程12周.收集治疗前后血清标本各一份,采用ELISA法检测患者血清SP -D浓度.结果 治疗前后平均血清SP- D浓度吸入沙美特罗替卡松粉剂治疗组患者分别为(148.2 ±65.7)μg/L和(89.2±53.2) μg/L,治疗前后血清平均SP-D水平差异有统计学意义(P＜0.05).单纯吸入沙美特罗粉剂组治疗前后患者血清SP-D浓度分别为(143.5±69.1)μg/L和(136.7±59.5)μg/L,治疗前后血清平均SP-D水平差异无统计学意义(P＞0.05).结论 稳定期COPD患者吸入沙美特罗替卡松粉剂治疗后血清SP -D浓度比治疗前降低,血清SP- D浓度检测可能成为一个潜在的COPD治疗的生物学检测指标.
目的 探討吸入沙美特囉替卡鬆粉劑對慢性阻塞性肺疾病(chronic obstructive pulmonary disease,COPD)穩定期患者血清肺錶麵活性物質相關蛋白D(surfactant associated protein D,SP-D)濃度的影響.方法 選擇Ⅲ級及Ⅳ級穩定期COPD患者84例,隨機分為沙美特囉(50μg)和沙美特囉替卡鬆粉劑(50 μg/500 μg)兩組,每組42例,每例患者均吸入2次/日,每次1吸,療程12週.收集治療前後血清標本各一份,採用ELISA法檢測患者血清SP -D濃度.結果 治療前後平均血清SP- D濃度吸入沙美特囉替卡鬆粉劑治療組患者分彆為(148.2 ±65.7)μg/L和(89.2±53.2) μg/L,治療前後血清平均SP-D水平差異有統計學意義(P＜0.05).單純吸入沙美特囉粉劑組治療前後患者血清SP-D濃度分彆為(143.5±69.1)μg/L和(136.7±59.5)μg/L,治療前後血清平均SP-D水平差異無統計學意義(P＞0.05).結論 穩定期COPD患者吸入沙美特囉替卡鬆粉劑治療後血清SP -D濃度比治療前降低,血清SP- D濃度檢測可能成為一箇潛在的COPD治療的生物學檢測指標.
목적 탐토흡입사미특라체잡송분제대만성조새성폐질병(chronic obstructive pulmonary disease,COPD)은정기환자혈청폐표면활성물질상관단백D(surfactant associated protein D,SP-D)농도적영향.방법 선택Ⅲ급급Ⅳ급은정기COPD환자84례,수궤분위사미특라(50μg)화사미특라체잡송분제(50 μg/500 μg)량조,매조42례,매례환자균흡입2차/일,매차1흡,료정12주.수집치료전후혈청표본각일빈,채용ELISA법검측환자혈청SP -D농도.결과 치료전후평균혈청SP- D농도흡입사미특라체잡송분제치료조환자분별위(148.2 ±65.7)μg/L화(89.2±53.2) μg/L,치료전후혈청평균SP-D수평차이유통계학의의(P＜0.05).단순흡입사미특라분제조치료전후환자혈청SP-D농도분별위(143.5±69.1)μg/L화(136.7±59.5)μg/L,치료전후혈청평균SP-D수평차이무통계학의의(P＞0.05).결론 은정기COPD환자흡입사미특라체잡송분제치료후혈청SP -D농도비치료전강저,혈청SP- D농도검측가능성위일개잠재적COPD치료적생물학검측지표.
Objective To determine the effect of inhaled salmeterol/fluticasone on serum surfactant protein D(SP- D) in patients with stable chronic obstructive pulmonary disease (COPD).Methods 84 COPD patients were randomly divided into two groups; group 1 ( n =42) were treated with salmeterol (50 μg) alone,and group 2 ( n =42) with salmeterol/fluticasone (50 μg/500 μg),each patient inhaled twice daily for 12 weeks.Serum samples were taken at baseline and after 12 weeks of treatment.The levels of serum SP-Dwere detected using ELISA.Results The average serum SP-D for patients were significantly decreased from ( 148.2 ± 65.7 ) μg/L to (89.2 ± 53.2) μg/L ( P ＜0.05 ) in patients who inhaled salmeterol/fluticasone.The average serum SP D for patients who inhaled salmeterol alone was (143.5 ± 69.1) μg/L and ( 136.7 ± 59.5) μg/L at baseline and after inhaled salmeterol were not significant (P ＞ 0.05).Conclusions The serum SP- D in patients with stable COPD decreases significantly after treatment with inhaled salmeterol/fluticasone,which may be a potential diagnostic biomarker for COPD treatment.
